NCT04823702View on ClinicalTrials.gov

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
Impaired Hepatic Function
Interventions
BIOLOGICAL

Aldafermin

Biological: Aldafermin (NGM282) Subcutaneous Injection

Trial Locations (3)

32809

NGM Clinical Study Site 111, Orlando

33014

NGM Clinical Study Site 110, Miami

78215

NGM Clinical Study Site 113, San Antonio

Sponsors
All Listed Sponsors
lead

NGM Biopharmaceuticals, Inc

INDUSTRY

NCT04823702 - Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function | Biotech Hunter | Biotech Hunter